Back

ESMO-GC 2023 - ESMO Gynaecological Cancers 2023

Feb 23 - Feb 24, 2023 | BarcelonaSpain

LARVOL is not affiliated with ESMO Gynaecological Cancers 2023 and all trademarks, logos, and brand names are property of their respective owners

Showing 16 abstracts linked to Trials

Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction by MORAb-202 (Farletuzumab Ecteribulin) in Human Ovarian Cancer (OV) Models

  • On-demand, Poster

NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models

  • On-demand, Poster

Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting

  • On-demand, Poster

Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group

  • On-demand, Poster